Houston, TX 的 膽道系統癌症 臨床試驗
18 項針對 膽道系統癌症 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
招募中2 期
- Research Site, Houston
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
招募中3 期
- Research Site, Houston
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
招募中1/2 期
- MD Anderson Cancer Center, GI Medical Oncology Dept, Houston
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
招募中1/2 期
- University of Texas MD Anderson Cancer Center ( Site 0316), Houston
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
招募中2 期
- Research Site, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Oncology Consultants, Houston
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
招募中1/2 期
- MD Anderson Cancer Center, Houston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Houston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- MD Anderson, Houston
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
招募中3 期
- Research Site, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The University of Texas, MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
招募中2 期
- Houston Methodist Hospital Cancer Center, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
其他城市的 膽道系統癌症 試驗
- Los Angeles, CA11 項研究
- Boston, MA11 項研究
- New York City, NY10 項研究
- Nashville, TN9 項研究
- Baltimore, MD8 項研究
- San Antonio, TX8 項研究
- Washington, DC7 項研究
- Arlington, VA7 項研究
- Pittsburgh, PA7 項研究
- Madison, WI6 項研究
- Dallas, TX6 項研究
- Cleveland, OH6 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。